ABL1 and acute lymphoblastic leukemia: Following the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia patients with autologous or allogeneic BCR-ABL specific CTLS, no major toxicity was observed, and all patients achieved a molecular or hematologic complete remission after T cell therapy upon the emergence of BCR-ABL specific T cells in the bone marrow [43].